IDXX Quote, Financials, Valuation and Earnings

Intuitive Surgical, Inc. has a net margin of 22.76% compared to IDEXX Laboratories, Inc.'s net margin of 27.89%. IDEXX Laboratories, Inc.'s return on equity of 69.08% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

IDEXX Laboratories, Inc. has a consensus price target of $750.23, signalling upside risk potential of 18.95%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 22.48%. Given that Intuitive Surgical, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than IDEXX Laboratories, Inc..

IDEXX Laboratories, Inc. has a beta of 1.667, which suggesting that the stock is 66.736% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. IDEXX Laboratories, Inc.'s net income of $248.2M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 48.24x while Intuitive Surgical, Inc.'s PE ratio is 63.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 11.87x versus 18.00x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 22.76% compared to IDEXX Laboratories, Inc.'s net margin of 34.4%. IDEXX Laboratories, Inc.'s return on equity of 69.08% beat Eli Lilly & Co.'s return on equity of 104.39%.

IDEXX Laboratories, Inc. has a consensus price target of $750.23, signalling upside risk potential of 18.95%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,206.07 which suggests that it could grow by 17.87%. Given that IDEXX Laboratories, Inc. has higher upside potential than Eli Lilly & Co., analysts believe IDEXX Laboratories, Inc. is more attractive than Eli Lilly & Co..

IDEXX Laboratories, Inc. has a beta of 1.667, which suggesting that the stock is 66.736% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. IDEXX Laboratories, Inc.'s net income of $248.2M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 48.24x while Eli Lilly & Co.'s PE ratio is 45.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 11.87x versus 14.30x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 22.76% compared to IDEXX Laboratories, Inc.'s net margin of 18.06%. IDEXX Laboratories, Inc.'s return on equity of 69.08% beat Merck & Co., Inc.'s return on equity of 39.63%.

IDEXX Laboratories, Inc. has a consensus price target of $750.23, signalling upside risk potential of 18.95%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.48%. Given that IDEXX Laboratories, Inc. has higher upside potential than Merck & Co., Inc., analysts believe IDEXX Laboratories, Inc. is more attractive than Merck & Co., Inc..

IDEXX Laboratories, Inc. has a beta of 1.667, which suggesting that the stock is 66.736% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.69% to investors and pays a quarterly dividend of $0.85 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. IDEXX Laboratories, Inc.'s net income of $248.2M is lower than Merck & Co., Inc.'s net income of $3B. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 48.24x while Merck & Co., Inc.'s PE ratio is 16.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 11.87x versus 4.70x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revvity, Inc. has a net margin of 22.76% compared to IDEXX Laboratories, Inc.'s net margin of 12.41%. IDEXX Laboratories, Inc.'s return on equity of 69.08% beat Revvity, Inc.'s return on equity of 3.2%.

IDEXX Laboratories, Inc. has a consensus price target of $750.23, signalling upside risk potential of 18.95%. On the other hand Revvity, Inc. has an analysts' consensus of $119.56 which suggests that it could grow by 19.67%. Given that Revvity, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Revvity, Inc. is more attractive than IDEXX Laboratories, Inc..

IDEXX Laboratories, Inc. has a beta of 1.667, which suggesting that the stock is 66.736% more volatile than S&P 500. In comparison Revvity, Inc. has a beta of 1.066, suggesting its more volatile than the S&P 500 by 6.609%.

IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity, Inc. offers a yield of 0.28% to investors and pays a quarterly dividend of $0.07 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Revvity, Inc. pays out 13.61% of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are larger than Revvity, Inc. quarterly revenues of $772.1M. IDEXX Laboratories, Inc.'s net income of $248.2M is higher than Revvity, Inc.'s net income of $95.8M. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 48.24x while Revvity, Inc.'s PE ratio is 48.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 11.87x versus 4.08x for Revvity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.